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ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease 
marked by frequent recurrence and metastasis and stagnant survival rates. To enhance 
molecular knowledge of HNSCC and define a non-coding RNA (ncRNA) landscape of 
the disease, we profiled the transcriptome-wide dysregulation of long non-coding 
RNA (lncRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA) using RNA-
sequencing data from 422 HNSCC patients in The Cancer Genome Atlas (TCGA). 307 
non-coding transcripts differentially expressed in HNSCC were significantly correlated 
with patient survival, and associated with mutations in TP53, CDKN2A, CASP8, PRDM9, 
and FBXW7 and copy number variations in chromosomes 3, 5, 7, and 18. We also 
observed widespread ncRNA correlation to concurrent TP53 and chromosome 3p loss, 
a compelling predictor of poor prognosis in HNSCCs. Three selected ncRNAs were 
additionally associated with tumor stage, HPV status, and other clinical characteristics, 
and modulation of their expression in vitro reveals differential regulation of 
genes involved in epithelial-mesenchymal transition and apoptotic response. This 
comprehensive characterization of the HNSCC non-coding transcriptome introduces 
new layers of understanding for the disease, and nominates a novel panel of transcripts 
with potential utility as prognostic markers or therapeutic targets.
INTRODUCTION
HNSCC is the sixth leading cancer worldwide, 
with an estimated 600,000 new cases annually and 
a 50% five-year mortality rate [1]. The molecular 
heterogeneity and diverse etiology of head and neck 
tumors remain prohibitive barriers to the development 
of improved treatments and prognostic tools. Previous 
characterization of molecular features in HNSCC [2–5], 
particularly with the aid of large-scale cancer genomics 
initiatives such as The Cancer Genome Atlas (TCGA) 
[6, 7], have generated important insights for stratifying 
HNSCCs and delineating tumor subtypes. However, 
these analyses, almost exclusively concentrated 
on the protein-coding genome, critically overlook 
alterations in the vast non-coding transcriptome that 
may substantially contribute to HNSCC pathogenesis 
and progression. 
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microRNAs (miRNAs) are the only class of non-
coding RNAs (ncRNAs) relatively well-investigated in 
HNSCC, with previous studies profiling their dysregulation 
[8–10], association with patient survival [11, 12], and 
involvement in apoptotic and oncogenic pathways [13, 14]. 
Long non-coding RNAs (lncRNAs) have also been 
increasingly implicated in tumor biology, yet beyond studies 
of previously cancer-associated transcripts such as HOTAIR, 
MALAT-1, and NEAT-1, their significance in HNSCC is 
sparsely characterized [15–17]. The involvement of PIWI-
interacting RNAs (piRNA) remains an even greater enigma, 
its dysregulation in breast, lung, and gastric cancers having 
only recently been uncovered [18].
Preliminary investigation of lncRNAs in HNSCC, 
coupled with the recent implication of piRNAs in cancers, 
highlights the need to systematically characterize ncRNA 
expression and functional significance in the HNSCC 
tumor population. Utilizing next-generation sequencing 
and clinical data from 422 HNSCC patients in TCGA, we 
profiled the global expression patterns and dysregulation 
of all three ncRNA classes in HNSCC. We sought to not 
only generate insights into the altered transcriptomic 
landscape of HNSCC, but also integrate novel findings 
with established molecular pathways in HNSCC 
pathogenesis and progression and with differences in 
tumor phenotype and patient outcome.
RESULTS
Non-coding RNA expression and dysregulation 
in HNSCC
Demographics and clinical characteristics for the 
total HNSCC cohort used in the study are provided in 
Supplementary Table 1. To identify HNSCC-dysregulated 
ncRNAs, we utilized all HNSCC tumor-paired adjacent 
normal RNA-sequencing data in TCGA on 15 June 2014. 
These data consisted of: (1) 40 tumor-normal RNA-seq 
datasets, for lncRNA profiling; and (2) 43 tumor-normal 
small RNA-seq datasets and Level 3 gene expression 
analyses, for piRNA and miRNA profiling, respectively 
(dataset IDs in Supplementary Dataset 1). ncRNA expression 
was obtained by alignment of sequencing datasets to custom 
gene annotations containing 113,438 lncRNA transcripts 
and 27,127 piRNAs, or extracted from corresponding 
TCGA Level 3 gene expression analyses profiling 1,046 
miRNAs. Using negative binomial-based differential 
expression testing, we identified 9,681 lncRNA transcripts, 
232 miRNAs, and 61 piRNAs significantly dysregulated 
(FDR < 0.05) in HNSCCs relative to paired normal tissue. 
We focused subsequent study on 596 intergenic lncRNAs 
(lincRNAs) exhibiting reliable expression and ≥ 4-fold 
dysregulation in HNSCCs (FDR < 0.0001) (Supplementary 
Dataset 2, Figure 1A–1B), while retaining all differentially 
expressed miRNAs and piRNAs as candidates 
(Supplementary Datasets 3–4; Figure 1C–1D). 
Our analysis confirmed the previously-reported 
dysregulation of several miRNAs in HNSCC, including 
downregulation of miR-375 [14], the miR-29 family 
[19], miR-204 [20], and miR-99 [21], and upregulation 
of miR-196 [22], miR-21 [23], and miR-31 [23, 24]. Our 
results also revealed miRNAs with unexplored roles in 
the context of HNSCC, including miR-654, previously 
associated with prostate metastasis [25] and hepatocellular 
carcinoma [26], and let-7c, encoded in a genomic cluster 
distinct from let-7 miRNAs harboring documented links to 
HNSCC [10, 27] (Figure 1c).  
Among lncRNAs, we confirm previously-reported 
downregulation of GAS5 and MEG-3 [28], and identify 
for the first time dysregulation of cancer-associated H19 
and PCAT-1 in HNSCCs. However, we observed only 
modest (< 4-fold) alterations in the expression of all four 
transcripts relative to normal (Supplementary Dataset 5). 
Furthermore, many other established, cancer-linked 
lncRNAs, including HOTAIR, MALAT-1, NEAT-1, and 
UCA-1, were found to be either extremely lowly expressed 
(mean and median cpm < 1) or insufficiently dysregulated 
in HNSCCs (Supplementary Dataset 5). Meanwhile, 
comparison of the HNSCC-dysregulated piRNAs to 
preliminary studies of their expression in other cancers 
yielded similarly sparse overlap, with only piR-34736 and 
piR-36318 previously identified in breast cancer [18]. 
Identification of dysregulated non-coding RNAs 
correlated to patient survival
After obtaining ncRNA expression in all remaining 
TCGA HNSCCs with clinical data (dataset IDs in 
Supplementary Dataset 6), we screened each ncRNA 
class for transcripts significantly associated with patient 
survival. Because patient age and HPV status are observed 
to produce distinct survival outcomes in HNSCC patients 
[1], we limited the cohorts for our initial screens to 
HPV- negative patients < 85 years of age. We next 
evaluated the ncRNAs for prognostic potential among all 
patients regardless of age or HPV status. Under univariate 
and multivariate Cox regression analyses in both cohorts, 
we identified 276 intergenic lncRNAs, 21 miRNAs, 
and 6 piRNAs significantly predictive of overall patient 
outcome (Supplementary Datasets 7–9). 2 ncRNAs 
ultimately selected for experimental validation exhibited 
prognostic significance both among HPV-negative, age 
<  85 patients and in the full tumor cohort (Figure 2).
Association of non-coding RNAs with known 
HNSCC genomic alterations
Multiple studies have identified compelling 
patterns of co-occurrence and synergistic interaction 
among genomic and molecular alterations in cancer 
[6, 29–32]. To locate the potential functions of survival-
associated ncRNAs in relationship to canonical HNSCC 
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Figure 1: Heatmaps of significantly differentially expressed non-coding RNAs in HNSCC. (A) Heatmap depicting normalized 
expression levels (in counts-per-million) of the 100 lincRNA transcripts with the largest magnitude of dysregulation in HNSCCs compared 
to paired normal samples (FDR < 0.0001). Inset highlights the 4 experimentally validated isoforms of lnc-JPH1-7. (B) Expression plot 
of lnc-JPH1-7 in HNSCCs compared to adjacent normal tissue. (C–D) Heatmaps depicting normalized expression levels (in counts-per-
million) of (D) 232 miRNAs (FDR < 0.05) and (E) 61 piRNAs (FDR < 0.05) dysregulated in HNSCC tumors, highlighting discussed or 
ultimately experimentally validated transcripts.
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driver events, we employed Wilcoxon rank-sum testing 
to identify correlations between ncRNA expression 
and tumor mutational status or copy number variation. 
TCGA HNSCC mutation and copy number calls were 
obtained from the Broad Institute GDAC Firehose, 
with attention restricted to 26 frequently occurring 
somatic mutations in HNSCCs [4] and 73 copy number 
alterations. Notably, expression levels of many ncRNAs 
were strongly correlated to TP53 mutation, as observed in 
256 among 276 survival-associated lincRNA transcripts 
(FDR < 0.0001), 12 among 21 prognostic miRNAs 
(p < 0.01), and 1 among 6 survival-associated piRNAs 
(p < 0.05) (Figure 3A). We also show frequent ncRNA 
association with mutations in CASP8, CDKN2A, histone 
methyltransferase PRDM9, and cyclin E, Notch, and 
c-Myc regulator FBXW7 (Supplementary Datasets 
11– 12, Figure 3A). Additionally, pairwise analyses 
between ncRNA expression and incidence of copy 
number variations revealed widespread correlations with 
3p, 5p, 7p, and 18q deletion, and 3q and 7q amplification 
(Supplementary Datasets 13–14, Figure 3B). 
A recent study found that HNSCCs containing 
both TP53 mutation and deletions on the chromosome 3p 
arm were dramatically associated with advanced tumor 
stage and poor clinical outcomes [6]. To explore the 
potential implications and molecular basis underlying this 
phenomenon, we further assessed the relationship between 
expression of our candidate ncRNAs and incidence of 
TP53-3p events. The high-risk TP53-3p cohort consisted 
of: (1) HNSCCs harboring both TP53 mutation and 3p 
deletion, and (2) all HPV-positive HNSCCs (which exhibit 
TP53 inactivation by HPV) harboring 3p deletion. 
In total, 269 of 276 survival-correlated lincRNAs 
(FDR < 0.05) and 11 prognostic miRNAs (p < 0.05), 
were significantly associated with TP53-3p co-occurrence 
(Supplementary Dataset 15). Among these were a number 
of miRNAs previously characterized in HNSCC, notably 
miR-29b-1, -2 [33], miR-370 [34], miR-126 [35], miR-337 
[36], miR-30e [37], and miR-106b [9]. Taken together, 
these findings suggest a substantial role for our identified 
ncRNAs in key oncogenic pathways and molecular 
signatures.
qRT-PCR validation and characterization of 
non-coding RNAs in HNSCC cell lines
Having attained a global perspective of the HNSCC 
non-coding transcriptome, we undertook a focused 
investigation of several ncRNAs by further evaluating 
their relationship to clinical features and their significance 
in vitro. One transcript from each ncRNA class was chosen 
for functional study: lnc-JPH1-7 (lncRNA), miR-654-3p 
(miRNA), and piR-34736 (piRNA). miR-654-3p was 
selected based on its novel identification as a differentially 
expressed miRNA in HNSCCs, while lnc-JPH1-7 and 
piR-34736 were selected based on novel dysregulation in 
HNSCC, as well as significant association with survival 
among both HPV-negative and HPV-positive patients 
(Figure 2). Dysregulation of the selected ncRNAs was 
verified by qRT-PCR using 2 normal oral epithelial cell 
lines compared to 5–6 established HNSCC cell lines 
(Supplementary Figure S2). 
lnc-JPH1-7, a 1,164-nt transcript located on 
chromosome 8q21, is upregulated by 35-fold in TCGA 
HNSCCs. We found that elevated lnc-JPH1-7 levels 
in HNSCCs associated not only with poor prognosis, 
methyltransferase KMT2D (MLL1) mutation, and 
concurrent TP53 mutation and 3p deletion, but also 
significantly correlated to advanced tumor stage (p = 0.02; 
Supplementary Figure S3a). Furthermore, higher median 
lnc-JPH1-7 expression was observed among HPV-
negative patients and patients reporting history of smoking 
(Supplementary Figure S3B-S3C). We subsequently 
manipulated the expression of lnc-JPH1-7 in vitro to 
evaluate its oncogenic characteristics. shRNA-mediated 
knockdown of lnc-JPH1-7 reduced the expression of 
EMT-promoting genes for N-cadherin (CDH-2) and 
Snail (SNAI1), as well as anti-apoptotic gene XIAP, in 
HNSCC cell lines UMSCC-10B and HN-30 (Figure 4A). 
Next we assessed the effects of lnc-JPH1-7 on apoptotic 
DNA fragmentation using the DNA double-strand break 
and apoptosis marker γ-H2AX. γ-H2AX accumulates in 
early apoptosis with the onset of DNA fragmentation, 
as a direct consequence of caspase activation [38]. 
Immunofluorescence showed significant upregulation 
of γ-H2AX in lnc-JPH1-7-knockdown cell lines, with 
many cells exhibiting pan-nuclear γ-H2AX staining, a 
defining characteristic of the apoptotic γ-H2AX response 
(Figure 4D) [39, 40]. We also observed significantly 
increased punctate γ-H2AX foci in non-pan-nuclear 
staining cells with manipulated lnc-JPH1-7 expression 
(Figure 4D).
miR-654-3p is downregulated by 2-fold in TCGA 
HNSCCs, with lower expression in tumors associated with 
increased incidence of FBXW7 mutation (Figure 3A, 3D). 
Although implicated in other malignancies, most notably 
in prostate cancer as a regulator of apoptosis and invasion 
[25], underexpression of miR-654-3p has not been 
previously identified in HNSCC. We found that median 
miR-654-3p levels are reduced in advanced-stage HNSCCs 
compared with early-stage tumors (Supplementary 
Figure S4A). Additionally, further knockdown of 
miR- 654-3p expression in HNSCC cell lines UMSCC-
10B and HN-30 led to the repression of E-cadherin and 
Caspase-9 gene expression (Figure 4B). Finally, piR-
34736 (DQ596670), upregulated by 2-fold in TCGA 
HNSCCs and correlated to patient survival and PRDM9 
mutation (Figure 3A, 3D), was recently observed to be 
downregulated in breast cancers, with uncharacterized 
functional significance [18]. To investigate the role 
of piR- 34736 in HNSCC malignancy, we suppressed 
piR- 34736 expression in the UMSCC- 10B and HN-30 
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cell lines, resulting in significantly increased Bax/Bcl2 
ratio and repression of EMT-mediator Vimentin (VIM) 
(Figure 4C). We also observed significant association 
between elevated piR-34736 expression and advanced 
tumor stage (p < 0.005; Supplementary Figure S4B), and 
increased median piR-34736 expression with tumor grade 
and recent smoking (Supplementary Figure S4C).
DISCUSSION
The recent implication of ncRNAs in a vast array 
of biological functions has established the non-coding 
transcriptome as a new paradigm in understanding and 
subverting disease processes. For malignancies such as 
HNSCC in which traditional genomic characterizations 
have produced minimal improvements in patient outcome, 
ncRNAs may represent a particularly promising avenue 
for novel diagnostic and therapeutic strategies. Here, 
we comprehensively analyzed the expression patterns 
of three classes of ncRNAs in HNSCC using RNA-
sequencing data from 422 TCGA HNSCC cases. Among 
the vast number of significantly differentially expressed 
miRNAs, lncRNAs, and piRNAs, we ultimately identified 
303 transcripts demonstrating both dysregulation in 
HNSCC and association with patient survival, most 
of which have not been previously linked to cancer 
pathogenesis and progression. Notably, many lncRNAs 
harboring well-documented links to other cancers were 
found to exhibit low expression or limited dysregulation 
in HNSCC. For instance, tumor suppressors GAS5 and 
MEG-3 were downregulated by less than 2-fold in tumors 
(Supplementary Dataset 5). HOTAIR, although reported 
to be upregulated in multiple malignancies, including 
head and neck tumors from certain anatomic sites 
[15, 16], was shown by our RNA-sequencing analysis 
to be expressed at very low levels (median cpm < 0.5) 
in HNSCCs overall. Similarly, our panel of dysregulated 
and survival-correlated piRNAs was largely distinct from 
those previously identified in lung, gastric [41], and breast 
[18] cancers. These findings underscore the importance 
Figure 2: Selected ncRNAs exhibiting significant correlation to HNSCC patient survival. (A–B) Kaplan-Meier curves 
showing survival outcomes according to relative high and low expression of (A) lnc-JPH1-7, (B) piR-34736 in HNSCC tumors. Association 
of these ncRNAs with patient survival is significant in both the full tumor cohort and among the subset of HPV-negative, age < 85 patients.
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Figure 3: Association of prognostic ncRNAs with somatic mutations and copy number variations in HNSCCs. 
(A) Heatmap showing widespread correlation between ncRNA expression level and select somatic mutations of high incidence in HNSCC 
tumors. ncRNAs are arranged alphabetically, with numeric position on heatmap indicated in source data. (B) Heatmap showing abundant 
correlations between ncRNA expression level and common CNVs in HNSCCs. ncRNAs are arranged alphabetically, with numeric position 
on heatmap indicated in Supplementary Dataset 10. (C–D) Notched boxplots depicting specific (C) ncRNA-CNV correlations and (D) 
ncRNA-mutation correlations for selected, survival-associated ncRNAs (Wilcoxon rank-sum, P < 0.05 for miRNA and piRNA; FDR < 0.1 
for lincRNAs). (E–F) Notched boxplots depicting specific (E) lincRNAs and (F) miRNAs exhibiting significant correlation in expression 
to concurrent loss of TP53 and 3p in HNSCCs (Wilcoxon rank sum, P < 0.05).
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of using unbiased sequencing approaches to globally 
evaluate ncRNAs in terms of both reliable expression 
and significant dysregulation. The limited applicability 
of previously identified cancer-associated ncRNAs to 
HNSCC acutely highlights the necessity of continuing 
to identify novel non-coding transcripts exhibiting both 
functional relevance and therapeutic potential in HNSCC. 
One notable challenge of studying ncRNAs 
is determining their precise contributions to disease 
pathogenesis and progression. To generate insight into the 
potential functions of our identified ncRNAs, we examined 
their expression in tumors in relationship to HNSCC 
genomic signatures, and observed a particularly compelling 
link between many ncRNAs and incidence of TP53 mutation. 
Several miRNAs and lncRNAs have been previously 
characterized in p53 regulatory networks [42, 43], including 
the p53-induced miR-34 family [44] and lincRNA-p21 [45], 
both of which facilitate large-scale transcriptional repression 
of genes in the p53 pathway. Thus, the discovery of abundant 
p53-ncRNA associations in HNSCC, while underscoring 
the widespread molecular alterations resulting from TP53 
loss alone, may also implicate many additional non-coding 
transcripts as active regulators of the p53 response or as 
mediators of its downstream effects. While p53-ncRNA 
networks represent a growing field of study, the nature 
of ncRNA interactions with other somatic mutations and 
genomic alterations has remained virtually unexplored 
and unevaluated. Extensive ncRNA correlations with 
CASP8, CDKN2A, PRDM9, and FBXW7 mutations, and 
with chromosome 3, 5, 7, and 18 copy number variations, 
suggest that the tumorigenic significance of these aberrations 
is administered at least in part by ncRNA activity. Functional 
investigation of these associations may yield valuable 
insights into how malignant transformation in general is 
facilitated through genomic and non-coding transcriptomic 
dependence. Specifically, the ncRNAs we have identified to 
be correlated with concurrent TP53 mutation and 3p deletion 
may be involved in mediating the mechanisms for their co-
occurrence in HNSCC and other malignancies [6] and for 
their synergistic tumorigenic effects. 
Figure 4: Effects of in vitro lnc-JPH1-7, miR-654-3p, and piR-34736 manipulation on expression of EMT and apoptosis 
genes. (A–C) Knockdown of lnc-JPH1-7, miR-654-3p, and piR-34736 led to the repression of EMT and anti-apoptotic genes in HNSCC 
cell lines (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t-test. (D) Immunofluorescence images showing increased expression of 
γ-H2AX, and significantly increased accumulation of γ-H2AX foci in UMSCC-10B and HN-30, following lnc-JPH1-7 knockdown.
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To substantiate the functional potential of our 
ncRNAs, we manipulated the expression of several 
transcripts in HNSCC cell lines and observed their 
resulting impact on key cancer-associated genes. All 
three ncRNAs selected for study were found to influence 
expression of genes involved in EMT and apoptosis, 
underscoring the importance of these pathways in 
HNSCC, and linking the prognostic significance of these 
ncRNAs to the regulation of migratory and invasive 
characteristics in HNSCCs. miR-654 exhibited negative 
regulation of E-cadherin and Caspase 9 in HNSCC cell 
lines, consistent with its proposed role of inhibiting 
prostate metastasis [25]. Meanwhile, although piR-
34736 was found to be underexpressed in breast cancers 
[18] and lnc-JPH1-7 was also identified in esophageal 
(ESCCAL-1) [46] and lung (LCAL80) [47] squamous cell 
carcinomas, their clinical and molecular significance has, 
up to now, remained uninvestigated. Here, we show that 
both ncRNAs may exert distinctively oncogenic functions, 
their increasing expression in HNSCCs correlated to 
both significantly reduced survival and advanced tumor 
stage, and their knockdown in HNSCC cell lines leading 
to the repression of EMT-promoting and anti-apoptotic 
genes. Moreover, suppression of lnc-JPH1-7 was also 
associated with accumulation of DNA double-strand 
break and apoptosis-associated γ-H2AX. Taken together, 
these results highlight the potential functional significance 
of our additional candidate ncRNAs, and underscore the 
relevance of all three ncRNA classes in tumorigenesis and 
metastasis.
Utilizing the comprehensive TCGA collection of 
next-generation sequencing and clinical data, we identified 
a panel of HNSCC-dysregulated ncRNAs correlated 
with patient survival, and characterized three transcripts 
in vitro to establish their roles in HNSCC pathogenesis 
and progression. Our results, while underscoring the vast 
array of ncRNAs whose links to HNSCC remain novel and 
unexplored, show that these transcripts are often involved 
in, and may significantly enhance, our understanding of 
molecular interplay even in the most central, well-studied, 
disease pathways and processes. By profiling the HNSCC 
non-coding transcriptome with unprecedented depth and 
scope and integrating its characteristics with established 
clinical and molecular features, this study provides a 
foundation for future endeavors to investigate ncRNAs in 
HNSCCs as well as other malignancies.
MATERIALS AND METHODS
TCGA RNA-sequencing and gene expression 
datasets
MapSplice-aligned TCGA BAM files were obtained 
from the UCSC Cancer Genomics Hub (https://cghub.
ucsc.edu/) on 15 June 2014 for paired tumor and adjacent 
normal pairs, and on 1 August 2014 for unpaired tumors. 
To investigate lncRNA expression, we downloaded RNA-
seq datasets for 40 tumor-adjacent normal pairs and 368 
additional unpaired tumors, and to investigate piRNA 
expression, we downloaded small RNA-seq datasets for 43 
tumor-adjacent normal pairs and 380 additional unpaired 
tumors. 
miRNA expression data were derived from TCGA 
Level 3 normalized gene expression datasets (https://
tcga-data.nci.nih.gov/tcga/findArchives.htm). To profile 
miRNAs, we downloaded miRNA-seq Level 3 analyses for 
the same cohort as used for piRNA expression profiling. The 
TCGA barcodes for all patients whose datasets were used in 
this study are provided in Supplementary Datasets 1 and 6.
Non-coding RNA expression analysis
miRNA read counts were extracted from the TCGA 
Level 3 gene expression analyses. lncRNA and piRNA 
read counts were generated from sequencing datasets 
via BEDtools coverageBed (https://github.com/arq5x/
bedtools2 ) [48] using lncRNA and piRNA annotation 
files. A lncRNA BED file containing 113,438 transcripts 
was obtained from LNCipedia 3.0 (http://lncipedia.
org/) [49], a database curating lncRNAs from sources 
including the Broad Institute, Ensembl, Gencode, Refseq, 
and NONCODE. A BED file comprising 27,127 piRNAs 
was created by extracting all human piRNAs from the 
NONCODE v4.0 non-coding RNA database (http://www.
noncode.org/) [50]. 
Read count tables were imported into edgeR v3.0 
(http://www.bioconductor.org/packages/release/bioc/
html/edgeR.html) [51], and lowly expressed ncRNAs 
(counts-per-million< 1in more than 50% of samples) were 
filtered from the analysis. Following TMM normalization, 
matched pair designs were applied to identify significantly 
differentially expressed ncRNAs between HNSCC and 
adjacent normal tissue. 
All miRNAs and piRNAs identified as differentially 
expressed in edgeR were retained as candidates. To 
identify dysregulated intergenic lncRNAs, we downloaded 
a comprehensive annotation of protein-coding genes from 
UCSC (http://genome.ucsc.edu/cgi-bin/hgTables) and 
removed all lncRNAs overlapping protein-coding exons. 
We further filtered candidate lncRNA transcripts based on 
cutoffs for fold change magnitude (≥ 4 between HNSCC 
and normal) and false discovery rate (FDR) ≤ 10–4. 
Clinical data
Clinical data for 422 HNSCC cases were downloaded 
from the TCGA Data Portal on 1 August 2014 (https://tcga-
data.nci.nih.gov/tcga/findArchives.htm). Reported patient 
outcomes are based on all-cause mortality. Patient HPV 
status was obtained from sequencing datasets archived 
on cBioPortal (http://www.cbioportal.org/public/) by the 
TCGA HNSCC analysis working group. For patients where 
sequencing-based HPV calls were unavailable, results from 
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PCR-based MassARRAY HPV detection assays and HPV 
in-situ hybridization assays were retrieved from the TCGA 
Data Portal. 
Association of ncRNA expression with patient 
survival
Survival analyses were performed using Cox 
proportional hazards models, with ncRNA expression in 
tumors established as a binary variable based on expression 
above or below the median. Because patient age and HPV 
status have been shown to profoundly influence molecular 
signatures and clinical outcomes in HNSCC, we limited 
our initial cohort to HPV-negative patients less than 85 
years of age, resulting in 343 for lincRNA survival analysis 
and 352 for miRNA and piRNA analyses (Supplementary 
Dataset 6). In our multivariate analysis, patient age was 
introduced as both a continuous and binary (age < or > 
= 75) to capture non-linear relationships between patient 
age and survival. P-values generated under this model 
for lincRNAs were corrected for multiple-hypothesis 
testing using the Benjamini-Hochberg false discovery rate 
correction, with a significance threshold of FDR < 0.05. 
ncRNAs ultimately selected for experimental validation 
were also evaluated under Cox analysis among all patients, 
regardless of age or HPV status.
Association of ncRNA expression with tumor 
mutations and copy number aberrations
Mutation calls for the TCGA tumors were obtained 
from mutation annotation files (maf) generated by the 
Broad Institute GDAC Firehose on 5 September 2014. 
We focused our analysis on 26 most frequently mutated 
genes in HNSCCs, as determined by whole exome 
sequencing of an independent tumor cohort by Stransky 
et al. [4]. A Wilcoxon rank sum test was employed to test 
for significant associations between ncRNA expression 
level (counts-per-million) and mutational status. P-values 
among lincRNAs were corrected for multiple comparisons 
testing using the Benjamini-Hochberg procedure.
Copy number variations for the TCGA tumors 
were obtained from the GISTIC2 pipeline in Firehose 
on 24 September 2014. Similarly, all 73 significant 
(99% confidence) focal amplifications and deletions 
were analyzed for correlation to ncRNA expression level 
using Wilcoxon rank sum tests, followed by Benjamini-
Hochberg correction of lincRNA p-values.
Association of ncRNA expression with tumor 
stage, grade, invasion, and patient HPV and 
smoking status
Correlations between ncRNAs selected for 
experimental validation and clinical features were 
performed using the Kruskal-Wallis test. To investigate 
ncRNA association with HPV status, clinical data and 
ncRNA expression data (cpm) from the full tumor cohorts 
were used. 
Analyses of ncRNA in relationship to tumor 
stage and grade, perineural invasion, and smoking were 
performed using the HPV-negative, age<85 cohorts. 
Patients with no available information for a given 
characteristic were filtered from analyses involving that 
variable. 
In tumor stage analyses, patients with Stage IVA, B, 
and C tumors were classified as “Stage IV.” In smoking 
status analyses, patients listed as “Current smoker” or 
“Current reformed smoker for < or = 15 years” were 
classified as “Recent Smokers,” while patients listed as 
“Current reformed smoker for > 15 years” were classified 
as “Reformed Smokers.”  
Cell culture
The non-cancerous oral epithelial cell lines 
OKF4, OKF6, HOK were gifts from the Rheinwald 
Lab at Harvard Medical School. They were cultured in 
Keratinocyte-SFM(1X) with L-glutamine, supplemented 
with 0.2 ng/mL human recombinant epidermal growth 
factor (EGF) , 25 ug/mL bovine pituitary extract (BPE), 
0.3 mM calcium chloride, and penicillin streptomycin. 
Upon attaining 30% confluency, they were cultured in 
equal parts supplemented Keratinocyte-SFM medium and 
DFK medium. DFK was made with equal parts DMEM 
and F-12 and supplemented with 0.2 ng/mL EGF, 25 ug/
mL BPE, 2mM L-glutamine, and penicillin streptomycin. 
Established HNSCC cell lines used in this study 
were UMSCC-10B (larynx), UMSCC-22B (larynx), 
HN-1 (pharynx), HN-12 (tongue), and HN-30 (pharynx), 
SCC-4 (tongue) and Cal-27 (tongue). UMSCC-10B and 
UMSCC-22B were gifts from Dr. Tom Carey, University 
of Michigan, and HN-1, HN-12, and HN-30 were gifts 
from Dr. J.S. Gutkind, National Institute for Dental and 
Craniofacial Research. SCC-4 and Cal-27 were purchased 
from the American Type Culture Collection. Cell lines 
were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS), 2% streptomycin sulfate, and 
2% L-glutamine, and incubated at 37°C in 5% CO
2
 and 
21% O
2
.
siRNA-mediated knockdown of lnc-JPH1-7
Select siRNA oligonucleotides targeting lnc-
JPH1-7 were custom synthesized (Life Technologies) 
with the following sequences: siRNA 1:  GCAUGUAUU 
UUGGUCAAUATT siRNA 2: GAAGUUUAGUAAACC 
AAAATT.
HNSCC cell lines were transfected with a 100 pmol 
pool containing  both lnc-JPH1-7 siRNAs or with a 
control scramble sequence, using Lipofectamine 2000 
(Life Technologies) per manufacturer’s instructions. 
Transfection efficiency for the siRNAs was determined 
Oncotarget51220www.impactjournals.com/oncotarget
using qRT-PCR (Supplementary Figure S5), with total 
RNA extraction performed 48–72 hours following 
transfection.
shRNA-mediated knockdown of miR-654 and 
piR-34736
shRNA sequences targeting miR-654 and piR-34736 
(listed in Supplementary Table 2) were PCR-amplified and 
directionally cloned into the pmiRZIP lentivector (SBI) at 
the BamH1/EcoR1 site. The inserts were confirmed using 
Sanger sequencing (GENEWIZ). 
HNSCC cell lines were transiently transfected 
with the miRZIP constructs using Lipofectamine 2000 
(Invitrogen), with empty vector used as a control. 
Transfection efficiency for the plasmids was determined 
using qRT-PCR (Supplementary Figure S5), with total RNA 
extraction performed 48–72 hours following transfection.
RNA isolation and cDNA synthesis
Total RNA was extracted using the SurePrep 
TrueTotal RNA Purification Kit (Fisher BioReagents). 
cDNA for miRNA and piRNA assays was synthesized 
from 1.0 µg total RNA using the QuantimiR RT Kit 
(System Biosciences). cDNA for lncRNA assays was 
synthesized  from 1.0 µg total RNA using Poly(A) 
Tailing Kit (Ambion) and M-MLV Reverse Transcriptase 
(Invitrogen) per manufacturer’s instructions. 
qRT-PCR
qRT-PCRs were performed using FastStart 
Universal SYBR Green Master Mix (Roche Diagnostics) 
and run on a StepOnePlus Real-Time PCR System 
(Applied Biosystems). Results were analyzed using the 
∆∆Ct method and normalized to GAPDH expression (or 
U6 for miRNAs and piRNAs). All primers were obtained 
from Eurofins Genomics and sequences are listed in 
Supplementary Table 2. Statistical significance was 
assessed using Student’s t-test.
γ-H2AX Immunofluorescence
UMSCC-10B and HN-30 were transfected with lnc-
JPH1-7 siRNA as previously described and cultured on 
cover slips. Cells were subsequently treated with 1 μg/mL 
cisplatin for 24 hours. 48-72 hours after transfection, cells 
were fixed with 4% paraformaldehyde and blocked in goat 
serum at room temperature, followed by incubation with 
anti-phospho-Histone H2A.X (JBW301) mouse monoclonal 
antibody (Cell Signaling Technology). Cells were then 
incubated with Alexa Fluor 594 donkey anti-mouse 
secondary antibody (Life Technologies) and counterstained 
with Hoechst. Immunofluorescence images were obtained 
at 63X using a Zeiss inverted fluorescence microscope, and 
AxioVision 4.8.2 software was used for image capture.
γ-H2AX foci scoring
γ-H2AX foci were quantified using the FociCounter 
program (http://focicounter.sourceforge.net/). For each 
sample, the average number of γ-H2AX foci per cell was 
determined using at least 7 images taken from different 
fields on the cover slip (containing ≥40 nuclei total). 
Statistical significance was assessed using Student’s t-test.
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